Welcome to our dedicated page for Igm Biosciences SEC filings (Ticker: IGMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGM Biosciences, Inc. (IGMS) SEC filings page on Stock Titan provides access to the company’s historical regulatory documents filed with the U.S. Securities and Exchange Commission. As a former Nasdaq-listed issuer, IGM Biosciences filed annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K that describe its clinical-stage biotechnology activities, financial position, collaboration revenues, operating expenses and risk factors related to its engineered IgM antibody platform.
Among the notable filings is a Form 8‑K dated July 1, 2025, in which IGM Biosciences reports entering into an Agreement and Plan of Merger with Concentra Biosciences, LLC and a merger subsidiary. This filing outlines the structure of the cash tender offer and subsequent merger, the treatment of common stock, stock options, restricted stock units and certain pre‑funded warrants, and the creation of contingent value rights tied to closing net cash and potential future dispositions of specified product candidates and intellectual property.
Investors researching IGMS can also review a Form 25 filed with the SEC, which notifies the removal of IGM Biosciences’ common stock from listing and registration on The Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. A later Form 15 filing certifies the termination of registration of the company’s common stock under Section 12(g) and the suspension of its duty to file reports under Sections 13 and 15(d), indicating that IGM Biosciences has deregistered its common stock and ceased ongoing Exchange Act reporting for that class of securities.
Stock Titan’s interface surfaces these filings in chronological order and can pair them with AI-powered summaries to highlight key points, such as changes in listing status, merger terms, cash thresholds, contingent value right mechanics and other material provisions. Users can quickly locate Forms 10‑K and 10‑Q for detailed historical financial and pipeline information, Forms 8‑K for material events, and the Form 25 and Form 15 that document the company’s transition from a publicly listed, reporting issuer to a wholly owned subsidiary following the Concentra transaction.
IGM Biosciences (IGMS) Principal Accounting Officer Steven Weber reported a sale of 486 shares of common stock on June 16, 2025. The transaction was executed at a weighted average price of $1.1992 per share, with individual trades ranging from $1.17 to $1.22.
Key details of the transaction:
- The sale was specifically conducted to cover tax withholding obligations related to the vesting of restricted stock units
- Following the transaction, Weber maintains direct beneficial ownership of 26,530 shares
- The Form 4 was filed on June 28, 2025, with signature by power of attorney through Misbah Tahir
This transaction represents a routine share sale for tax purposes rather than a discretionary trading decision by the insider. The relatively small transaction size and its purpose suggest minimal significance for investor sentiment.